Zhang Fuxun, Qin Feng, Yuan Jiuhong
Andrology Laboratory, West China Hospital, Sichuan University, Chengdu, China.
Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
Front Pharmacol. 2021 May 20;12:643641. doi: 10.3389/fphar.2021.643641. eCollection 2021.
Peyronie's disease (PD) is a localized fibrotic lesion of the penis that has adverse effects on men's health. In this review, we summarized the molecular mechanisms and pharmacotherapies of PD. A literature search was conducted using PubMed and Cochrane Library during 2001-2020. Although no oral or topical medication demonstrated efficacy in monotherapy of PD, several intralesional medications have yielded promising results. Currently, the effective strategy in management of PD should be combined modality therapy, including but not limited to pharmacotherapy, mechanical therapy, and psychotherapy. Meanwhile, basic research is still necessary to facilitate the development of novel and more reliable treatments. In future, more attention should be given simultaneously to epigenetic changes, inflammatory cytokines, the abnormal wound-healing process, and profibrotic and anti-fibrotic factors to provide more options for this refractory disease.
佩罗尼氏病(PD)是阴茎的一种局限性纤维化病变,对男性健康有不良影响。在本综述中,我们总结了佩罗尼氏病的分子机制和药物治疗方法。在2001年至2020年期间,使用PubMed和考科蓝图书馆进行了文献检索。尽管没有口服或局部用药在佩罗尼氏病的单一疗法中显示出疗效,但几种病灶内用药已取得了有希望的结果。目前,佩罗尼氏病管理的有效策略应是联合治疗,包括但不限于药物治疗、机械治疗和心理治疗。同时,基础研究对于促进新型且更可靠治疗方法的开发仍然是必要的。未来,应同时更加关注表观遗传变化、炎性细胞因子、异常的伤口愈合过程以及促纤维化和抗纤维化因子,以便为这种难治性疾病提供更多选择。